Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

152 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study.
Santoni M, Myint ZW, Büttner T, Takeshita H, Okada Y, Lam ET, Gilbert D, Küronya Z, Tural D, Pichler R, Grande E, Crabb SJ, Kemp R, Massari F, Scagliarini S, Iacovelli R, Vau N, Basso U, Maruzzo M, Molina-Cerrillo J, Galli L, Bamias A, De Giorgi U, Zucali PA, Rizzo M, Seront E, Popovic L, Caffo O, Buti S, Kanesvaran R, Kopecky J, Kucharz J, Zeppellini A, Fiala O, Landmesser J, Ansari J, Giannatempo P, Rizzo A, Zabalza IO, Monteiro FSM, Battelli N, Calabrò F, Porta C. Santoni M, et al. Among authors: tural d. Cancer Immunol Immunother. 2023 Sep;72(9):2961-2970. doi: 10.1007/s00262-023-03469-5. Epub 2023 May 29. Cancer Immunol Immunother. 2023. PMID: 37248424 Free PMC article.
Pembrolizumab in patients with advanced upper tract urothelial carcinoma: a real-world study from ARON-2 project.
Rizzo A, Buti S, Giannatempo P, Salah S, Molina-Cerrillo J, Massari F, Kopp RM, Fiala O, Galli L, Myint ZW, Tural D, Soares A, Pichler R, Mennitto A, Abahssain H, Calabrò F, Monteiro FSM, Albano A, Mollica V, Giudice GC, Takeshita H, Santoni M; ARON Working Group. Rizzo A, et al. Among authors: tural d. Clin Exp Metastasis. 2024 Oct;41(5):655-665. doi: 10.1007/s10585-024-10296-0. Epub 2024 Jun 8. Clin Exp Metastasis. 2024. PMID: 38850317
Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer.
Chi KN, Rathkopf D, Smith MR, Efstathiou E, Attard G, Olmos D, Lee JY, Small EJ, Pereira de Santana Gomes AJ, Roubaud G, Saad M, Zurawski B, Sakalo V, Mason GE, Francis P, Wang G, Wu D, Diorio B, Lopez-Gitlitz A, Sandhu S; MAGNITUDE Principal Investigators. Chi KN, et al. J Clin Oncol. 2023 Jun 20;41(18):3339-3351. doi: 10.1200/JCO.22.01649. Epub 2023 Mar 23. J Clin Oncol. 2023. PMID: 36952634 Free PMC article. Clinical Trial.
Treatment Patterns and Attrition in Metastatic Renal Cell Carcinoma: Real-Life Experience from the Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database.
Bölek H, Sertesen E, Kuzu OF, Tural D, Sim S, Nahit Şendur MA, Uçar G, Işık S, Hacıoğlu B, Çiçin İ, Arslan Ç, Göksu SS, Sever ÖN, Karaçin C, Karadurmuş N, Özgüroğlu M, Yekedüz E, Ürün Y. Bölek H, et al. Among authors: tural d. Clin Genitourin Cancer. 2024 Nov 29;23(1):102282. doi: 10.1016/j.clgc.2024.102282. Online ahead of print. Clin Genitourin Cancer. 2024. PMID: 39709686
Sequential Use of Sorafenib and Regorafenib in Hepatocellular Cancer Recurrence After Liver Transplantation: Treatment Strategies and Outcomes.
Ozbay MF, Harputluoglu H, Karaca M, Tekin O, Şendur MAN, Kaplan MA, Sahin B, Geredeli C, Teker F, Tural D, Saglam S, Çil T, Bilici A, Erol C, Kalkan Z, Bayram E, Selvi O, Gültürk İ, Göksu SS, Tatlı AM. Ozbay MF, et al. Among authors: tural d. Cancers (Basel). 2024 Nov 20;16(22):3880. doi: 10.3390/cancers16223880. Cancers (Basel). 2024. PMID: 39594835 Free PMC article.
Enfortumab Vedotin Following Platinum Chemotherapy and Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma: A Retrospective Data from the ARON-2EV Study.
Fiala O, Massari F, Basso U, Giannatempo P, Grande E, Buti S, Myint ZW, De Giorgi U, Pichler R, Grillone F, Ürün Y, Calabrò F, Bourlon MT, Galli L, Kanesvaran R, Roviello G, Kucharz J, Rizzo M, Park SH, Cerbone L, Seront E, Messina C, Molina-Cerrillo J, Santini D, Yano A, Incorvaia L, Catalano M, Pinto A, Formisano L, Soares A, Facchini G, Fornarini G, Poprach A, Rebuzzi SE, Nasso C, Spinelli GP, Angel M, Stellato M, Tural D, Aurilio G, Epstein I, Carrozza F, Monteiro FSM, Benedetti G, Büchler T, Ortega C, Zakopoulou R, Battelli N, Porta C, Bellmunt J, Gupta S, Santoni M. Fiala O, et al. Among authors: tural d. Target Oncol. 2024 Nov;19(6):905-915. doi: 10.1007/s11523-024-01099-0. Epub 2024 Oct 1. Target Oncol. 2024. PMID: 39354179 Free PMC article.
Comparison of the efficacy of sunitinib and pazopanib in patients with advanced non-clear renal cell carcinoma.
Yildirim HC, Bayram E, Chalabiyev E, Majidova N, Avci T, Güzel HG, Kapar C, Uzun M, Perkin P, Akgül F, Yildirim SS, Sali S, Yildiz A, Kazaz SN, Hendem E, Arcagok M, Tufan G, Yildirim U, Akgul OF, Arslan Ç, Taban H, Sahin E, Caglayan M, Esen R, Öksüzoğlu B, Guven DC, Kaplan MA, Araz M, Basaran M, Cubukcu E, Gokmen E, Cicin I, Algin E, Semiz HS, Tural D, Ozturk B, Erdogan AP, Sari M, Kara O, Erman M. Yildirim HC, et al. Among authors: tural d. J Chemother. 2024 Sep 10:1-12. doi: 10.1080/1120009X.2024.2403051. Online ahead of print. J Chemother. 2024. PMID: 39257075
152 results